Botanical extracts and compounds from Schinus plants and methods of use

Patent metadata

Field	Value
Publication number	US-11065261-B2
Application number	US-201916290543-A
Country	US
Kind code	B2
Filing date	Mar 1, 2019
Priority date	Jul 10, 2015
Publication date	Jul 20, 2021
Grant date	Jul 20, 2021

Abstract

This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

First claim

The invention claimed is:

1. A pharmaceutical formulation consisting of
(a) therapeutically effective amounts of: a compound having Formula (I) or a salt thereof

and, optionally, an antibiotic other than (I); and
(b) an amount of a pharmaceutically acceptable excipient.

2. The pharmaceutical formulation of claim 1 in the form of a particle, bead, tablet, capsule, or pill.

3. The pharmaceutical formulation of claim 1 in the form of a lotion, liquid, or gel.

4. The pharmaceutical formulation of claim 1 , wherein the formulation contains said antibiotic.

5. A method of treating or preventing a bacterial infection comprising administering to a subject an effective amount of a pharmaceutical formulation consisting of
(a) therapeutically effective amounts of: a compound having Formula (I) or a salt thereof

and, optionally, an antibiotic other than (I); and
(b) an amount of a pharmaceutically acceptable excipient.

6. The method of claim 5 , wherein the subject is at risk of a bacterial infection due to being diagnosed with an abscess, furuncle, cellulitis, folliculitis, atopic dermatitis, psoriasis, impetigo, septic arthritis, brain abscess, burn wound, venous ulcer, diabetic foot ulcer, surgical wound, carbuncle, or meningitis.

7. The method of claim 5 , wherein administering is contacting the skin of subject with the pharmaceutical formulation.

8. The method of claim 5 , wherein the formulation contains said antibiotic.

9. The method of claim 5 , wherein the subject is diagnosed with a bacterial infection.

10. The method of claim 5 , wherein the subject is diagnosed with bacteremia, pneumonia, staphylococcal food poisoning, necrotizing pneumonia, necrotizing fasciitis, scalded skin syndrome, post-operation bacterial infection, medical device bacterial infection, bacterial infection of the skin, soft tissue bacterial infection, or toxic shock syndrome.

11. A pharmaceutical formulation consisting of
(a) therapeutically effective amounts of: a compound having Formula (I) or a salt thereof

and, optionally, an antibiotic other than (I); and
(b) an amount of a pharmaceutically acceptable excipient.

12. The pharmaceutical formulation of claim 11 in the form of a particle, bead, tablet, capsule, or pill.

13. The pharmaceutical formulation of claim 11 in the form of a lotion, liquid, or gel.

14. The pharmaceutical formulation of claim 11 wherein the formulation contains said antibiotic.

15. A method of treating or preventing a bacterial infection comprising administering to a subject an effective amount of a pharmaceutical formulation consisting of (a) therapeutically effective amounts of: a compound having Formula (I) or a salt thereof

and, optionally, an antibiotic other than (I), and
(b) an amount of a pharmaceutically acceptable excipient.

16. The method of claim 15 , wherein the subject is at risk of a bacterial infection due to being diagnosed with an abscess, furuncle, cellulitis, folliculitis, atopic dermatitis, psoriasis, impetigo, septic arthritis, brain abscess, burn wound, venous ulcer, diabetic foot ulcer, surgical wound, carbuncle, or meningitis.

17. The method of claim 15 , wherein administering is contacting the skin of subject with the pharmaceutical formulation.

18. The method of claim 15 , wherein the formulation contains said antibiotic.

19. The method of claim 15 , wherein the subject is diagnosed with a bacterial infection.

20. The method of claim 15 , wherein the subject is diagnosed with bacteremia, pneumonia, staphylococcal food poisoning, necrotizing pneumonia, necrotizing fasciitis, scalded skin syndrome, post-operation bacterial infection, medical device bacterial infection, bacterial infection of the skin, soft tissue bacterial infection, or toxic shock syndrome.

Assignees

• Univ Emory

Inventors

• Quave Cassandra L
• Lyles James
• Porras-Brenes Gina
• Tang huaqiao

Classifications

• A61K31/575

  substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title

• A61K36/22

  Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title